---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-25-000131"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:51:43.074316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rallybio posts Q3 net income of $16.0M on $20M REV102 sale; RLYB116 data expected Q4 2025

## Summary
- Revenue $0.2M vs $0.3M YoY; R&D expenses fell to $4.1M (from $8.2M); G&A $3.0M (from $4.1M).
- Net income $16.0M ($0.36/share) vs net loss $11.5M in Q3 2024; includes $20M from sale of REV102 interest.
- Cash and securities $59.3M as of Sept 30; expected to fund operations through 2027.
- Completed Cohort 1 dosing of RLYB116 confirmatory PK/PD study; data on track for Q4 2025.
- RLYB332 development plans being evaluated; preclinical data show superior PD vs comparator molecules.

## SEC filing metadata
- accession: 0001739410-25-000131
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/0001739410-25-000131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-25-000131
- JSON: https://secwatch.observer/filing/0001739410-25-000131.json
- Plain text: https://secwatch.observer/filing/0001739410-25-000131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.